The UBT251 injection for CKD developed by UNITED LAB has received approval for new drug clinical trials from the U.S. FDA
United Lab's wholly-owned subsidiary United BioTech (Zhuhai Hengqin) Co., Ltd. has developed the innovative drug UBT251 injection, which has been approved by the U.S. FDA to conduct Phase II clinical trials for chronic kidney disease (CKD). Previously, this indication was approved by the National Medical Products Administration of China on January 20, 2025. UBT251 is a long-acting GLP-1/GIP/GCG tri-target receptor agonist, marking an enhancement in the company's competitiveness in the biopharmaceutical field
According to the Zhitong Finance APP, UNITED LAB (03933) announced that its wholly-owned subsidiary, UNITED BIOTECH (Zhuhai Hengqin) Co., Ltd., has independently developed the Class 1 innovative drug UBT251 injection, which has received approval from the U.S. Food and Drug Administration (FDA) to conduct Phase II clinical trials for chronic kidney disease (CKD) indications. Previously, the CKD indication was approved for clinical trials by the National Medical Products Administration of China on January 20, 2025.
UBT251 is a long-acting GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide)/GCG (glucagon) tri-target receptor agonist. The company is the first in China and the second globally to obtain clinical trial approval for a long-acting GLP-1/GIP/GCG tri-agonist prepared by chemical synthesis of peptides. Currently, multiple indications, including adult type 2 diabetes, overweight or obesity, and CKD, have received drug clinical trial approvals in both China and the United States, and have entered the clinical trial phase in China first.
In the future, the company will continue to focus on new product development and enhance its competitiveness and creativity in the biopharmaceutical industry, expecting to create greater returns for the company and its shareholders
